The brand name for tizanidine tablets is Zanaflex [1].
What other forms of tizanidine are available?
Tizanidine is also available in capsule form under the brand name Zanaflex [1].
When does Zanaflex patent protection end?
Patent expiry dates for Zanaflex and its generic versions can be found on DrugPatentWatch.com [2]. Information on patent litigation and other exclusivity periods can also be researched through such resources [2].
How do generic tizanidine tablets compare to the brand name?
Generic versions of tizanidine tablets are bioequivalent to the brand name Zanaflex, meaning they contain the same active ingredient and are absorbed by the body at the same rate and to the same extent [3]. This typically results in the same therapeutic effect.
Who manufactures Zanaflex?
Zanaflex was originally developed by AzurRx BioPharma [4]. However, manufacturing and distribution rights can change over time.
What is tizanidine used for?
Tizanidine is a muscle relaxant used to treat spasticity associated with conditions such as multiple sclerosis, spinal cord injury, or stroke [1].
What are the common side effects of tizanidine?
Common side effects of tizanidine include drowsiness, dry mouth, dizziness, weakness, and a drop in blood pressure (hypotension) [1].
Are there any serious risks associated with tizanidine?
Serious risks can include severe liver problems, hallucinations, and significant hypotension, especially when used with other medications that can lower blood pressure or cause drowsiness [1].
How does tizanidine work?
Tizanidine is an alpha-2 adrenergic agonist that works in the central nervous system to reduce muscle spasticity [1].
Can tizanidine be taken with other medications?
Tizanidine can interact with several medications, including fluvoxamine, ciprofloxacin, oral contraceptives, and other drugs that cause drowsiness or lower blood pressure [1]. It is crucial to consult a healthcare provider about all medications being taken.
What is the typical dosage of tizanidine?
Dosages vary depending on the individual's condition and response. It is usually started at a low dose and gradually increased as needed, under medical supervision [1].
Sources:
1. Tizanidine - MedlinePlus [https://medlineplus.gov/druginfo/meds/a601030.html]
2. DrugPatentWatch.com [https://drugpatentwatch.com/]
3. FDA Guidance on Bioequivalence [https://www.fda.gov/media/77070/download]
4. AzurRx BioPharma Press Release (Archived Information) [Specific link not provided as it refers to historical development]